This Week in Psychedelics

Groundbreaking Enthea announcement makes ketamine-assisted therapy an employee benefit; could psychedelics treat postpartum depression?

September 22, 2023

This Week...

Enthea, the first and only licensed provider of health benefit plans that cover psychedelic-assisted therapies, announced nationwide availability of ketamine-assisted therapy as an available employee benefit.

Similar to the way employers can offer dental and vision coverage as ancillary benefits, they can now offer ketamine therapy as a covered treatment. Here’s more:

Reunion Neuroscience announced that it has been cleared by the FDA to initiate its Phase II study of RE104 (a novel serotonergic psychedelic compound) for the treatment of postpartum depression.

Postpartum depression (PPD) is one of the most common medical complications during and after pregnancy, and is estimated to affect approximately 10-15% of patients in the United States.

After administration, Reunion’s RE104 rapidly converts to the clinically-active serotonergic form of the drug. Phase I clinical data indicated that RE104 produces a pharmacology similar to psilocybin with a reduced duration of the psychoactive experience. Check it out:

A new CPCR (Center for Psychedelic & Consciousness Research) study was published in Frontiers of Psychiatry. It included the largest prospective survey of naturalistic psilocybin use associated with improvement in mental health and well being to date. The results indicate that on average participants showed significant reductions in depressed mood, anxiety, and personal burnout, and significant increases in cognitive flexibility and spiritual well-being that were still detectable up to two months after the experience. Here’s more:

Did You Know?

Did you know psychedelics are now showing promise as an analgesic for patients with certain headache disorders and cancer pain diagnoses?

Psychedelics such as LSD and psilocybin are thought to alter pain perception through direct serotonin receptor agonism, anti-inflammatory effects, and synaptic remodeling. Researchers reviewed 21 articles that assessed the effects of psychedelics in treating various pain states. The results were featured in the journal Anesthesiology, which you can access here: